NCT06962137View on ClinicalTrials.gov

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

August 30, 2030

Conditions
Gastric Cancer Adenocarcinoma MetastaticGastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Interventions
DRUG

zolbetuximab

The investigational product, Zolbetuximab, is a sterile lyophilized powder preparation with the chimeric monoclonal antibody Zolbetuximab as the active pharmaceutical ingredient.

OTHER

Retrospective cohort, no intervention

No intervention

Trial Locations (6)

3000

UZ Leuven, Leuven

Unknown

UZA, Antwerp

Cliniques Universitaires Saint-Luc Brussels, Brussels

HUB, Brussels

UZ Gent, Ghent

AZ Delta Roeselare, Roeselare

All Listed Sponsors
lead

Universitaire Ziekenhuizen KU Leuven

OTHER